Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company whose news flow centers on drug development milestones, scientific data presentations, financial updates, and capital markets activity. Public communications describe a focus on late-stage ALXN1840 for Wilson disease and MNPR-101-based radiopharmaceutical programs for imaging and treating advanced cancers.
News items for Monopar commonly include clinical and scientific results, such as data from the ALXN1840-WD-204 copper balance study and pooled long-term neurological and safety analyses in Wilson disease. The company also reports on presentations at major medical meetings, including the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting and the American Neurological Association (ANA) Annual Meeting, as well as publications in peer-reviewed journals like the Journal of Hepatology.
Investors and observers can also find updates on radiopharmaceutical programs, including progress in Phase 1 imaging and therapeutic trials with MNPR-101-Zr and MNPR-101-Lu, and regulatory developments such as U.S. Food and Drug Administration authorization for an Expanded Access Program in advanced solid tumors. In addition, Monopar issues press releases on financial results, describing quarterly performance, research and development spending, and general and administrative expenses, alongside information on cash resources and capital-raising transactions.
Further topics in Monopar’s news include capital markets events, such as underwritten offerings of common stock and pre-funded warrants, share repurchase agreements with existing stockholders, and inclusion in the Russell 3000 and Russell 2000 indexes. Readers interested in MNPR news can use this page to follow these developments and review how the company describes the evolution of its Wilson disease and radiopharmaceutical programs over time.
Monopar Therapeutics (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC have partnered with The University of Texas Health Science Center at Tyler to develop urokinase plasminogen activator receptor targeted radio-immunotherapeutics (uPRITs) for severe COVID-19 treatment. UTHSCT will conduct essential preclinical and clinical studies, leveraging a $2 million NIH grant aimed at improving outcomes for hospitalized COVID-19 patients. This collaboration aims to expedite the development of uPRITs for potential first-in-human trials at UTHSCT.
Monopar Therapeutics (MNPR) announced a partnership with Aragen Bioscience to accelerate the development of urokinase plasminogen activator receptor targeted radio-immunotherapeutics (uPRITs) for treating severe COVID-19. The collaboration aims to select a lead uPRIT candidate based on the MNPR-101 antibody scaffold, advancing towards IND-enabling studies. This partnership is crucial in targeting aberrantly activated immune cells to combat severe lung injury associated with COVID-19. The initiative reflects a strong commitment to innovative therapeutic solutions amidst ongoing health challenges.
Monopar Therapeutics (Nasdaq: MNPR) announced its initiative to develop a COVID-19 test aimed at triaging patients based on their risk of severe respiratory failure. The test will utilize Monopar's antibody, ATN-658, to measure soluble urokinase plasminogen activator receptor (suPAR) levels in patient plasma. Preliminary studies suggest elevated suPAR correlates with a 17-fold increase in severe outcomes. Monopar is also collaborating with NorthStar Medical Radioisotopes on a precision therapeutic targeting aberrant immune cells in severe COVID-19 cases, potentially improving patient management.
Monopar Therapeutics (MNPR) has announced a strategic partnership with NorthStar Medical Radioisotopes and IsoTherapeutics Group to develop Radio-Immuno-Therapeutics (RITs) aimed at treating severe COVID-19. The collaboration will utilize Monopar’s experimental antibody MNPR-101, modified by IsoTherapeutics to couple with therapeutic radioisotopes from NorthStar. This initiative seeks to advance clinical trials that target immune cells implicated in severe COVID-19 outcomes. The partnership builds on previous successful collaborations and aims to improve patient outcomes significantly.
Monopar Therapeutics (MNPR) reported a net loss of $1.4 million, or $0.14 per share, for Q2 2020, an increase from a $0.9 million loss in Q2 2019. Cash and cash equivalents stood at $12.5 million. Key developments include a 50/50 collaboration with NorthStar to create Radio-Immuno-Therapeutics to treat severe COVID-19, utilizing Monopar's MNPR-101. Both the Validive and camsirubicin clinical trials are on track to commence dosing in H2 2020. R&D expenses rose to $0.8 million due to clinical preparations and staffing.
Monopar Therapeutics (Nasdaq: MNPR) and NorthStar Medical Radioisotopes announced a provisional patent application for a treatment targeting the Urokinase Plasminogen Activator Receptor (uPAR) in severe COVID-19 patients. This application aims to create precision radioimmunotherapeutics (uPRITs) that selectively destroy activated white blood cells, potentially reducing mortality rates from cytokine storms. The collaboration aims to leverage both companies' expertise to enhance treatment efficacy. If granted, the patent will provide exclusivity for the use of uPRITs in severe COVID-19 and respiratory diseases.
Monopar Therapeutics and NorthStar Medical Radioisotopes have formed a 50/50 collaboration to develop Radio-Immuno-Therapeutics (RITs) targeting severe COVID-19. This partnership aims to combine NorthStar's expertise in medical radioisotope production with Monopar's MNPR-101 antibody. The goal is to create a selective treatment that can kill aberrantly activated immune cells responsible for cytokine storms in COVID-19 patients. The collaboration plans to conduct development programs to potentially transform Monopar's monoclonal antibodies into effective RITs against severe COVID-19.
Monopar Therapeutics (Nasdaq: MNPR) reported its first quarter 2020 financial results, highlighting a net loss of $1.1 million ($0.10 per share), improved from a $1.4 million loss in Q1 2019. Cash and cash equivalents amounted to $12.6 million. The company is advancing its Validive Phase 2b/3 clinical trial, now set to start in the second half of 2020, with a focus on reducing enrollment challenges due to COVID-19. Additionally, the camsirubicin Phase 2 clinical trial is progressing in collaboration with GEIS, targeting advanced soft tissue sarcoma.